AIM ImmunoTech Inc
AIM3.035USD
+0.205+7.24%
Market hours （ET）Quotes delayed by 15 min
219.40MMarket Cap
LossP/E TTM
More Details of AIM ImmunoTech Inc Company
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Company Info
Ticker SymbolAIM
Company nameAIM ImmunoTech Inc
IPO dateJul 12, 1996
CEOMr. Thomas K. Equels, Esq., J.D.
Number of employees21
Security typeOrdinary Share
Fiscal year-endJul 12
Address2117 Sw Highway 484
CityOCALA
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code32801
Phone13524487797
Websitehttps://aimimmuno.com/
Ticker SymbolAIM
IPO dateJul 12, 1996
CEOMr. Thomas K. Equels, Esq., J.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.88K
+0.54%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+60.53%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
+31.96%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
+232.64%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.88K
+0.54%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+60.53%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
+31.96%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
+232.64%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jul 12
Updated: Sat, Jul 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Equels (Thomas K)
1.41%
The Vanguard Group, Inc.
0.88%
Kellner (Theodore D)
0.71%
Deutsch (Todd A)
0.62%
BlackRock Institutional Trust Company, N.A.
0.25%
Other
96.12%
Shareholders
Shareholders
Proportion
Equels (Thomas K)
1.41%
The Vanguard Group, Inc.
0.88%
Kellner (Theodore D)
0.71%
Deutsch (Todd A)
0.62%
BlackRock Institutional Trust Company, N.A.
0.25%
Other
96.12%
Shareholder Types
Shareholders
Proportion
Individual Investor
12.10%
Investment Advisor
4.36%
Investment Advisor/Hedge Fund
1.03%
Hedge Fund
0.74%
Venture Capital
0.11%
Other
81.65%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
68
140.24K
18.35%
-21.39K
2025Q1
83
99.85K
13.13%
-1.64M
2024Q4
79
10.59M
16.61%
-4.59M
2024Q3
75
14.47M
24.79%
+767.12K
2024Q2
74
13.00M
23.76%
+4.07M
2024Q1
77
8.58M
17.30%
-354.68K
2023Q4
77
8.35M
17.07%
-576.60K
2023Q3
80
8.49M
17.46%
-718.46K
2023Q2
77
5.43M
11.23%
-869.40K
2023Q1
81
5.73M
11.83%
-1.19M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Equels (Thomas K)
38.88K
5.09%
+210.00
+0.54%
Jun 13, 2025
The Vanguard Group, Inc.
24.44K
3.2%
+4.56K
+22.91%
Mar 31, 2025
Kellner (Theodore D)
19.70K
2.58%
+19.68K
+196850.00%
Apr 11, 2025
Deutsch (Todd A)
17.16K
2.25%
--
--
Dec 19, 2024
BlackRock Institutional Trust Company, N.A.
6.98K
0.91%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
5.31K
0.7%
+673.00
+14.50%
Mar 31, 2025
Mitchell (William M)
5.22K
0.68%
+1.97K
+60.53%
Apr 11, 2025
Rodino (Peter W III)
4.02K
0.53%
+5.00
+0.12%
Apr 04, 2025
Appelrouth (Stewart L.)
3.89K
0.51%
+670.00
+20.82%
Dec 31, 2024
Renaissance Technologies LLC
3.18K
0.42%
+575.00
+22.07%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 03, 2025
Merger
100<1
Date
Type
Ratio
Mar 03, 2025
Merger
100<1
